OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Structure Therapeutics Inc. (NASDAQ:GPCR) by 8.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,520 shares of the company’s stock after acquiring an additional 1,520 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Structure Therapeutics were worth $529,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of GPCR. Spire Wealth Management purchased a new position in Structure Therapeutics in the 4th quarter worth approximately $243,000. JPMorgan Chase & Co. grew its holdings in shares of Structure Therapeutics by 302.3% in the third quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company’s stock worth $1,489,000 after purchasing an additional 25,500 shares during the last quarter. Mariner LLC purchased a new position in shares of Structure Therapeutics in the fourth quarter worth $665,000. Barclays PLC raised its holdings in Structure Therapeutics by 64.5% during the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock valued at $3,562,000 after buying an additional 31,815 shares during the last quarter. Finally, Principal Financial Group Inc. raised its holdings in Structure Therapeutics by 230.0% during the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company’s stock valued at $23,936,000 after buying an additional 380,115 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR opened at $23.89 on Wednesday. The firm has a market capitalization of $1.37 billion, a P/E ratio of -32.28 and a beta of -1.69. The stock has a 50 day moving average price of $20.98 and a 200-day moving average price of $26.75. Structure Therapeutics Inc. has a 52-week low of $13.22 and a 52-week high of $62.74.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). On average, equities analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on GPCR. Citigroup assumed coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They issued a “buy” rating and a $60.00 price objective on the stock. HC Wainwright cut their target price on Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Monday. Finally, William Blair began coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an “outperform” rating for the company. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $78.00.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.